In this file photo taken on December 8, 2020 a member of staff draws the Pfizer-BioNTech COVID-19 vaccine out of a phial at the Southmead Hospital, Briston. (Photo: Graeme Robertson / AFP / POOL)
The Vatican health service will begin vaccinating employees and Vatican citizens against COVID-19 using the Pfizer vaccine, the director of the Vatican health service told Vatican News.
"Only through a widespread and capillary immunization of the population will it be possible to obtain real advantages in terms of public health to achieve control of the pandemic," Dr. Andrea Arcangeli said Dec. 11.
"Therefore, it is our duty to offer all residents, employees and their families the opportunity to be immunized against this dreaded disease," he said.
The Vatican News story said the vaccination program would begin "in the first months" of 2021, but a Vatican official posted on Facebook Dec. 11 that employees were told they would be vaccinated in January.
"It is important to educate everyone that the vaccine is not only to protect one's own health, but also that of other people," the Vatican News story said.
Dr. Arcangeli said the Pfizer vaccine, developed in conjunction with BioNTech, was chosen because it is the leading candidate for both European and U.S. approval, is already being used in England and has tested at 95% effective.
"Other vaccines produced with different methods may be introduced after evaluating their efficacy and full safety," he added.
Vatican News did not ask Dr. Arcangeli about reports that in the early stages of testing, the Pfizer/BioNTech vaccine was tested on cells lines produced from cells that originally came from an aborted fetus. The vaccine, however, is not one of those that use abortion-derived cell lines in the manufacturing process.
The Pontifical Academy for Life and Catholic bishops around the world, including the chairmen of the U.S. bishops' doctrine and pro-life committees, have said it is not immoral to be vaccinated with vaccines like the Pfizer/BioNTech product because any connection they have to aborted fetuses is extremely remote. Such cells derived from those fetuses were used only in a testing phase but not in the production phase.
Vatican News did ask Dr. Arcangeli about concerns over the safety of the vaccine.
"It is understandable that there may be some fears about a vaccine that has been developed in such a short time, but there have been very rigorous tests on safety," he said.
For the time being, he said, the Vatican will not be recommending the vaccination of anyone under age 18 since "studies including this age group have not yet been carried out."
As an independent country, the Vatican has its own health service, with doctors' offices, a pharmacy, a laboratory, a walk-in clinic and first-aid stations. Many of the services are free to employees and their family members as well as retirees; the service covers about 15,000 people, including the pope and cardinals resident in Rome.
….As we enter the first months of 2022, we are asking readers like you to help us keep UCA News free.
For the last 40 years, UCA News has remained the most trusted and independent Catholic news and information service from Asia. Every week, we publish nearly 100 news reports, feature stories, commentaries, podcasts and video broadcasts that are exclusive and in-depth, and developed from a view of the world and the Church through informed Catholic eyes.
Our journalistic standards are as high as any in the quality press; our focus is particularly on a fast-growing part of the world - Asia - where, in some countries the Church is growing faster than pastoral resources can respond to – South Korea, Vietnam and India to name just three.
And UCA News has the advantage of having in its ranks local reporters who cover 23 countries in south, southeast, and east Asia. We report the stories of local people and their experiences in a way that Western news outlets simply don’t have the resources to reach. And we report on the emerging life of new Churches in old lands where being a Catholic can at times be very dangerous.
With dwindling support from funding partners in Europe and the USA, we need to call on the support of those who benefit from our work.